These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 2809678)
1. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. Gribben JG; Goldstone AH; Linch DC; Taghipour G; McMillan AK; Souhami RL; Earl H; Richards JD J Clin Oncol; 1989 Nov; 7(11):1621-9. PubMed ID: 2809678 [TBL] [Abstract][Full Text] [Related]
2. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP. Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209 [TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768 [TBL] [Abstract][Full Text] [Related]
4. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. Philip T; Armitage JO; Spitzer G; Chauvin F; Jagannath S; Cahn JY; Colombat P; Goldstone AH; Gorin NC; Flesh M N Engl J Med; 1987 Jun; 316(24):1493-8. PubMed ID: 3295541 [TBL] [Abstract][Full Text] [Related]
5. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397 [TBL] [Abstract][Full Text] [Related]
7. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057 [TBL] [Abstract][Full Text] [Related]
8. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report. Carella Am; Carlier P; Congiu A; Occhini D; Meloni G; Anselmo AP; Mandelli F; Mazza P; Tura S; Mangoni L Leukemia; 1991; 5 Suppl 1():68-71. PubMed ID: 1890870 [TBL] [Abstract][Full Text] [Related]
9. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120 [TBL] [Abstract][Full Text] [Related]
11. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958 [TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
13. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717 [TBL] [Abstract][Full Text] [Related]
14. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169 [TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. Freedman AS; Takvorian T; Anderson KC; Mauch P; Rabinowe SN; Blake K; Yeap B; Soiffer R; Coral F; Heflin L J Clin Oncol; 1990 May; 8(5):784-91. PubMed ID: 2332768 [TBL] [Abstract][Full Text] [Related]
16. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521 [TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow. Santini G; De Souza C; Congiu AM; Nati S; Marino G; Soracco M; Sertoli MR; Rubagotti A; Spriano M; Vassallo F; Rossi E; Vimercati R; Piaggio G; Figari O; Benvenuto F; Abate M; Truini M; Ravetti JL; Ribizzi I; Damasio E Leuk Lymphoma; 1999 Apr; 33(3-4):321-30. PubMed ID: 10221512 [TBL] [Abstract][Full Text] [Related]
18. Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors. Verdonck LF; Dekker AW; Vendrik PJ; van Kempen ML; Schornagel JH; Rozenberg-Arska M; de Gast GC Cancer; 1987 Aug; 60(3):289-95. PubMed ID: 3297283 [TBL] [Abstract][Full Text] [Related]
19. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732 [TBL] [Abstract][Full Text] [Related]
20. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]